PMID- 35207441
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230721
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 12
IP  - 2
DP  - 2022 Jan 20
TI  - Asthma and COVID-19 Associations: Focus on IgE-Related Immune Pathology.
LID - 10.3390/life12020153 [doi]
LID - 153
AB  - Management of patients with asthma during the coronavirus disease 2019 (COVID-19) 
      pandemic is a concern, especially since asthma predisposes patients to 
      respiratory problems. Interestingly, asthma characterized by type 2 inflammation, 
      also known as T-helper type 2-high endotype, displays a cellular and molecular 
      profile that may confer protective effects against COVID-19. The results of 
      experimental and clinical studies have established the actions of immunoglobulin 
      E (IgE) in inducing airway hyperreactivity and weakening an interferon-mediated 
      antiviral response following respiratory viral infection. Robust evidence 
      supports the beneficial effect of the anti-IgE biologic treatment omalizumab on 
      reducing respiratory virus-induced asthma exacerbations and reducing the 
      frequency, duration, and severity of respiratory viral illness in patients with 
      asthma. Indeed, accumulating reports of patients with severe asthma treated with 
      omalizumab during the pandemic have reassuringly shown that continuing omalizumab 
      treatment during COVID-19 is safe, and in fact may help prevent the severe course 
      of COVID-19. Accordingly, guidance issued by the Global Initiative for Asthma 
      recommends that all patients with asthma continue taking their prescribed asthma 
      medications, including biologic therapy, during the COVID-19 pandemic. The impact 
      of biologic treatments on patients with asthma and COVID-19 will be better 
      understood as more evidence emerges.
FAU - Wang, Chung-Jen
AU  - Wang CJ
AD  - Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 
      22056, Taiwan.
FAU - Cheng, Shih-Lung
AU  - Cheng SL
AUID- ORCID: 0000-0003-0111-3157
AD  - Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 
      22056, Taiwan.
AD  - Department of Chemical Engineering and Materials Science, Yuab Ze University, 
      Taoyuan City 32003, Taiwan.
FAU - Kuo, Sow-Hsong
AU  - Kuo SH
AD  - Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 
      22056, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220120
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC8874771
OTO - NOTNLM
OT  - COVID-19
OT  - IgE
OT  - asthma
OT  - biologics
OT  - omalizumab
COIS- The authors declare no commercial or financial conflict of interest.
EDAT- 2022/02/26 06:00
MHDA- 2022/02/26 06:01
PMCR- 2022/01/20
CRDT- 2022/02/25 01:12
PHST- 2021/11/18 00:00 [received]
PHST- 2022/01/15 00:00 [revised]
PHST- 2022/01/19 00:00 [accepted]
PHST- 2022/02/25 01:12 [entrez]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/02/26 06:01 [medline]
PHST- 2022/01/20 00:00 [pmc-release]
AID - life12020153 [pii]
AID - life-12-00153 [pii]
AID - 10.3390/life12020153 [doi]
PST - epublish
SO  - Life (Basel). 2022 Jan 20;12(2):153. doi: 10.3390/life12020153.